IATROGENIC CUSHING'S SYDROME AND USE OF TOCILIZUMAB IN SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITIS - A CASE REPORT.
Abstract
Cushing's syndrome refers to signs and symptoms caused by excess free plasma glucocorticoids. We report a case of iatrogenic Cushing's syndrome due to prolonged use of systemic steroids in systemic juvenile idiopathic arthritis and use of newer biologic tocilizumab as a treatment in systemic juvenile idiopathic arthritis.
Full Text:
PDFReferences
Stratakis CA.Cushing syndrome in pediatrics. Endocrinology Metabolism Clinics of North America.2012;41:79.
Nieman LK, Biller BM, Findling JW et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
Saag KG, Emkey R , Schnitzer TJ et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
Yokota S, Miyamae T, Imagawa T et al. Clinical Study of Tocilizumab in children with systemiconset juvenile idiopathic arthritis. Clin Rev Allergy Immunol.2005; 28:231-238.
Nelson, text book of pediatrics 20th edition.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An Initiative of The Tamil Nadu Dr MGR Medical University